Brief: Immix Unit Presents Interim Data, With 90% Overall Response Rate In Relapsed Or Refractory Multiple Myeloma At NXC-201 Therapeutic Dose From Its Phase 1 Expansion Trial At The 5Th European Car T-Cell Meeting
09/02/2023 18:47
Feb 9 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA SUBSIDIARY NEXCELLA, INC. PRESENTS
42-PATIENT
INTERIM DATA, WITH 90% OVERALL RESPONSE RATE IN RELAPSED OR
REFRACTORY MULTIPLE MYELOMA AT NXC-201 THERAPEUTIC DOSE FROM ITS
PHASE 1 EXPANSION TRIAL AT THE 5TH EUROPEAN CAR T-CELL MEETING
Source text for Eikon: ID:nGNX4CT2RX
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary